Diagnostics acquisition

Thermo Fisher Scientific has completed its acquisition of blood test systems provider Phadia.

Thermo Fisher Scientific has completed its acquisition of blood test systems provider Phadia. Phadia is based in Uppsala, Sweden and develops, manufactures and markets complete blood test systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases.

"We are pleased to complete the acquisition of Phadia, which significantly enhances our presence in high-growth specialty diagnostics markets by adding leading allergy and autoimmunity diagnostic tests," said Marc N. Casper, president and chief executive officer of Thermo Fisher. "Phadia provides us with growth opportunities in an under-penetrated US market and allows us to leverage our strong presence in emerging geographic markets."

Phadia will become part of Thermo Fisher's Specialty Diagnostics business.

For more information on the companies visit their websites at www.phadia.com and www.thermofisher.com